Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Silexion Therapeutics ( (SLXN) ) has provided an update.
On July 9, 2025, Silexion Therapeutics announced positive preclinical results for SIL204, demonstrating significant efficacy in human lung cancer cell lines. The study highlighted SIL204’s potential as a versatile therapeutic for KRAS-driven cancers, supporting its innovative lipid-conjugated delivery system. The company is preparing for a Phase 2/3 clinical trial in 2026 and is conducting additional studies on a new KRAS mutation, which could establish SIL204 as a potential pan-KRAS treatment.
The most recent analyst rating on (SLXN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Silexion Therapeutics stock, see the SLXN Stock Forecast page.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics has significant financial difficulties with zero revenue and negative equity, posing major risks. Technical analysis indicates a bearish trend, and speculative valuation metrics reflect the high-risk nature of the stock. However, promising corporate developments, such as the SIL204 partnership and positive preclinical results, offer potential upside if clinical success is achieved.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, which are common oncogenic drivers in human cancers. The company is advancing its next-generation siRNA candidate, SIL204, and has shown promising results in preclinical studies.
Average Trading Volume: 1,660,362
Technical Sentiment Signal: Sell
Current Market Cap: $7.08M
For an in-depth examination of SLXN stock, go to TipRanks’ Overview page.